In order to systematically explore and better understand the structure-activityrelationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a–1x and 1ha–1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or mixture thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.
Spirocyclic inhibitors of serine proteases for the treatment of hcv infections
申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:EP2631238A1
公开(公告)日:2013-08-28
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.